Genetico has invested in biotech startup Retinostar, which develops advanced gene therapy drugs for the treatment of genetic and age-related eye diseases. Investment in the form of a convertible loan will amount to ₽20 million and will be used to validate ophthalmic disease models and conduct animal studies to select the most effective drug candidates and prepare for the start of preclinical studies.